share_log

Avenue Therapeutics | S-3: Registration statement for specified transactions by certain issuers

SEC announcement ·  Jan 25 05:15
Summary by Futu AI
Avenue Therapeutics, Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 24, 2024, for the registration of 33,080,598 shares of common stock. The registration statement includes a preliminary prospectus detailing the proposed sale of shares by selling stockholders from time to time after the effective date of the Registration Statement. The sale may occur on the Nasdaq Capital Market or through private transactions at fixed or negotiated prices. The company will not receive any proceeds from the sale of shares by the selling stockholders. The registration statement also outlines the rights and obligations of the selling stockholders, including the potential methods of sale, such as block trades, broker transactions, or directly to purchasers. Avenue Therapeutics, a specialty pharmaceutical company, has indicated that the registration is part of its efforts to satisfy certain registration rights granted to the selling stockholders. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI'.
Avenue Therapeutics, Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 24, 2024, for the registration of 33,080,598 shares of common stock. The registration statement includes a preliminary prospectus detailing the proposed sale of shares by selling stockholders from time to time after the effective date of the Registration Statement. The sale may occur on the Nasdaq Capital Market or through private transactions at fixed or negotiated prices. The company will not receive any proceeds from the sale of shares by the selling stockholders. The registration statement also outlines the rights and obligations of the selling stockholders, including the potential methods of sale, such as block trades, broker transactions, or directly to purchasers. Avenue Therapeutics, a specialty pharmaceutical company, has indicated that the registration is part of its efforts to satisfy certain registration rights granted to the selling stockholders. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI'.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.